This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
Uniqure CEO Matt Kapusta told a group of investors at a private dinner on Tuesday that the Trump White House “doesn’t like all the drama” inside the Food and Drug Administration, just a week after the company said the agency had upended its plan to seek a speedy approval for a gene therapy to treat Huntington’s disease.
The decision to appoint longtime cancer chief Rick Pazdur as the agency’s top drug regulator — a job offer Pazdur initially declined but then accepted — is a sign of how seriously the administration is taking the FDA dysfunction, Kapusta also said.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
